Letter to the Editor

Volume 16, Number 2, April 2025, pages 235-238

CD19 Expression in B-Cell Lymphomas and Clinical Considerations in the Evolving Landscape of CD19-Targeted Therapy

Over the last decade, CD19-targeted therapies have transformed the treatment landscape for relapsed or refractory B-cell lymphoma. CD19-directed chimeric antigen receptor T-cells (CAR-Ts), including axicabtagene ciloleucel [1], lisocabtagene maraleucel [2], tisagenlecleucel [3] and brexucabtagene autoleucel [4], have proven to be highly efficacious in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Anti-CD19 monoclonal antibody tafasitamab is approved in the second-line setting, in combination with lenalidomide, for DLBCL patients with no intention to proceed to transplant [5]. Loncastuximab tesirine, a CD19-targeted antibody-drug conjugate, is also an option for relapsed or refractory DLBCL [6, 7]. As the use of CD19-directed therapies increases, it will be important to study patterns of CD19 expression, CD19 antigen escape, and the association between CD19 expression and the efficacy of CD19-targeted therapy. There is limited modern real-world data regarding CD19 expression and a lack of consensus regarding the optimal use and sequencing of CD19-directed therapies. Herein, we report a single-center retrospective study of CD19 expression in B-cell non-Hodgkin lymphoma patients and provide an up-to-date discussion on CD19-targeted therapies, including sequencing, CD19 loss and efficacy in cases with low or absent CD19 expression.

We identified 288 patients with B-cell non-Hodgkin lymphoma who were seen at Harbor-UCLA Medical Center in Torrance, CA, USA, from 2014 to 2023 (Table 1). The most common lymphoma histologies were DLBCL (49.7%), follicular lymphoma (13.2%), marginal zone lymphoma (7.6%), high-grade B-cell lymphoma (6.6%) and mantle cell lymphoma (4.2%). Biopsies were obtained per standard clinical practice, and CD19 testing was performed at the pathologist’s discretion and not for the purpose of this study. Of the 228 patients with biopsy results available from the time of diagnosis, CD19 expression status was reported for 92 patients (40.4%). Flow cytometry (95.7%) was the primary modality of CD19 expression analysis, with immunohistochemistry (4.3%) used in a small number of cases.

Click to view

Table 1. CD19 Expression Analysis at Diagnosis and Relapse

At the time of diagnosis, three patients (3.3%) were CD19-negative (one with plasmablastic lymphoma, one with DLBCL and one with non-Hodgkin B-cell lymphoma not otherwise specified), and one DLBCL patient (1.1%) had dim CD19 expression by flow cytometry. At relapse, the rate of repeat biopsy was 48.4%. There were 75 biopsies performed at the time of relapse or refractory disease, with CD19 testing done in 46.7% of biopsies. The only CD19-negative relapse biopsy was for a patient with plasmablastic lymphoma, whose CD19 status was unknown at the time of diagnosis. There were no cases of CD19 expression loss. Three patients received anti-CD19 CAR-T therapy (without post-CAR-T biopsy results available), and no patients received tafasitamab or loncastuximab tesirine.

Previous studies have shown that 2-12% of all B-cell lymphomas are CD19-negative [1, 4, 6, 8-10], and 1-33% have low CD19 expression [3, 6, 11, 12]. Certain types of B-cell lymphomas (plasmablastic lymphoma and primary effusion lymphoma) are characterized by the lack of expression of mature B-cell markers, including CD19. In our single-center retrospective cohort of patients with B-cell non-Hodgkin lymphoma, CD19 expression was analyzed and reported in 41.9% of all biopsies, and less than 5% of all B-cell lymphomas had absent or dim CD19 expression. The rate of CD19 antigen escape in the present study was 0%, which is expected as there were no biopsies after CD19-targeted therapy. While the rate of repeat biopsy at relapse (48.4%) and the percentage of biopsies with CD19 expression reported (41.9%) are suboptimal, this may reflect real-world clinical practice. Additional limitations of this study include its modest sample size and lack of CD19 expression analysis after CD19-targeted therapy.

When a clinician is considering the implementation of CD19-directed therapy (CAR-T, tafasitamab, loncastuximab tesirine), it is reasonable to assume that the lymphoma will be CD19-positive in > 90% of cases in the absence of prior CD19-based therapy. Nevertheless, there is some evidence that CD19-targeted therapies may still be effective in lymphomas with low or negative CD19 expression. In the ZUMA-1 trial of axicabtagene ciloleucel in relapsed/refractory high-grade B-cell lymphomas, there was no significant difference in overall response rate (ORR) (85% vs. 75%) or ongoing response rate (43% vs. 50%) between CD19-positive and CD19-negative lymphomas [1]. Similar results were demonstrated with tisagenlecleucel for relapsed high-grade B-cell lymphomas with comparable complete response rate (CRR) (40% vs. 29%), ORR (49% vs. 50%), and median overall survival (12.5 months vs. 10.3 months) observed between CD19-positive and CD19-negative/low lymphomas [3, 11]. In a translational study of tisagenlecleucel, there was no association between baseline CD19 expression and CAR-T cellular kinetics/expansion [11]. These findings indicate that axicabtagene ciloleucel and tisagenlecleucel may operate at least partially independently of CD19 and can be utilized in high-grade B-cell lymphomas with low or absent CD19 expression.

In the ZUMA-2 trial of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma, there were no significant differences in ORR (95% vs. 100%), ongoing response rate (57% vs. 100%) or 6-month progression-free survival (79% vs. 100%) between CD19-positive and CD19-negative tumors, with all three patients with CD19-negative tumors achieving a complete remission with ongoing response [4]. These results suggest that brexucabtagene autoleucel can be effective in CD19-negative mantle cell lymphoma.

Lastly, loncastuximab tesirine has also demonstrated benefits in lymphomas with low or absent CD19 expression. In the phase 1 LOTIS-1 trial, pre-treatment CD19 expression correlated with pharmacodynamic parameters; however, there was no correlation between CD19 expression and response [6]. Among three patients with 0% CD19 expression at diagnosis, the ORR was 67%. In a subgroup analysis of 59 patients from the phase 2 LOTIS-2 trial, including nine patients with low or undetectable CD19 expression, there was no significant difference in ORR between CD19-positive lymphomas (ORR = 54%) and lymphomas with low or undetectable CD19 (ORR = 44%) [12].

With the multitude of management strategies available for relapsed or refractory B-cell lymphoma, the practical application of sequential CD19-targeted therapy is a topic of ongoing clinical investigation. Multiple studies have described success with re-infusion of CAR-T [1, 10, 13]; however, the optimal order for sequencing different CD19-directed therapies is unclear. In the phase 2 LOTIS-2 trial of loncastuximab tesirine for relapsed or refractory high-grade B-cell lymphoma in the third-line setting and beyond, 14 patients received prior CAR-T therapy, and 16 patients went on to receive CAR-T after loncastuximab tesirine [7]. In the 14 CAR-T treated patients (biopsy was required to ensure CD19 positivity prior to loncastuximab tesirine), loncastuximab tesirine had an ORR of 48% with a CRR of 25%, which was not statistically significantly different from CAR-T-naive patients. A subgroup analysis of 14 patients from LOTIS-1/2 who went on to receive CAR-T after disease progression on loncastuximab tesirine revealed an ORR of 50% and CRR of 43% with CAR-T therapy [14]. Together, these results demonstrate the efficacy of loncastuximab tesirine after CAR-T and CAR-T after loncastuximab tesirine.

There is no evidence to support the use of tafasitamab after CAR-T therapy; however, CAR-T has been used as an effective salvage therapy after progression on tafasitamab and lenalidomide. In the phase 2 L-MIND study of tafasitamab and lenalidomide, two patients received CAR-T therapy after progression on tafasitamab and lenalidomide, one of whom achieved a complete remission [5]. A compelling case series was published describing two patients with CD19-negative relapse after tafasitamab [15], both of whom later regained CD19 expression and went on to receive CD19-directed CAR-T. These results suggest that tafasitamab may result in prolonged CD19 blockade or downregulation, and while subsequent CD19-based therapy can be used, it should be used prudently and ideally after a CD19-targeting holiday. For instance, a CD20-directed bispecific antibody or a Bruton tyrosine kinase (BTK) inhibitor [16] could be used after the failure of CD19-based therapy.

The principle of CD19 antigen escape was initially a clinical concern after early trials for CAR-T therapy in B-cell acute lymphoblastic leukemia showed high rates of CD19-negative relapse [17]. Loss of CD19 expression after CD19-targeted therapy has been reported in B-cell lymphomas at a rate of 0-27% [1, 4, 14]. While further research regarding mechanisms of CD19 loss is warranted, the clinical ramifications of CD19 antigen escape may be less consequential, given the efficacy of axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene maraleucel and loncastuximab tesirine in lymphomas with low or absent CD19 expression [1, 3, 4, 6, 11].

In conclusion, CD19 is expressed in > 90% of B-cell lymphomas, and CD19 antigen escape has been reported after CD19-targeted therapy. Multiple CD19-based therapies have demonstrated efficacy in patients with low or negative CD19 expression. Evidence supports the use of CAR-T therapy after tafasitamab or loncastuximab tesirine, and loncastuximab tesirine after CAR-T failure. As CD19-targeted therapies expand in utilization and potentially move up in the treatment paradigm, further research is needed regarding their efficacy in CD19-negative lymphomas and the optimal sequencing of therapies.

Acknowledgments

The authors would like to acknowledge the Harbor-UCLA Hematopathology Lab for assistance with pathologic analysis.

Financial Disclosure

This research project received no external funding from any government, industry, or private sources. Sarah Tomassetti has received financial support from Novartis, Merck, Principia Biopharma, Sanofi, Seagen and Rigel Pharmaceuticals. Joseph Marshalek and Xin Qing have no financial disclosures.

Conflict of Interest

The authors have no conflicts of interest to disclose.

Informed Consent

Harbor-UCLA Medical Center Institutional Review Board (IRB) approval was obtained (IRB number 18CR-32663-01). Informed consent was waived due to the retrospective nature of the study. Identifiable patient information was removed at the time of data analysis.

Author Contributions

ST designed the study and implemented the software for patient procurement. XQ analyzed biopsy samples. JM collected, analyzed, and curated data. JM prepared the original version of the manuscript. All authors were involved in manuscript editing. ST was responsible for project supervision. All authors have read and agreed to the published version of the manuscript.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531-2544.
   doi pubmed
2. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-1684.
   doi pubmed
3. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45-56.
   doi pubmed
4. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.
   doi pubmed
5. Duell J, Maddocks KJ, Gonzalez-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021;106(9):2417-2426.
   doi pubmed
6. Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634-2645.
   doi pubmed
7. Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, et al. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024;109(4):1184-1193.
   doi pubmed
8. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood. 1984;63(6):1424-1433.
   pubmed
9. Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood. 1988;71(1):13-29.
   pubmed
10. Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38(27):3119-3128.
    doi pubmed
11. Awasthi R, Pacaud L, Waldron E, Tam CS, Jager U, Borchmann P, Jaglowski S, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
    doi pubmed
12. Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, et al. CD19 expression by IHC alone is not a predictor of response to Loncastuximab Tesirine: results from the LOTIS-2 clinical trial and quantitative systems pharmacology modeling. Blood. 2022;140(Supplement 1):9548-9550.
13. Aydilek E, Klein-Scory S, Thomson J, Nilius-Eliliwi V, Vangala D, Schroers R, Wulf G, et al. Repeated infusions of brexucabtagene-autoleucel in relapsed/refractory mantle cell lymphoma. Hemasphere. 2023;7(9):e949.
    doi pubmed
14. Thapa B, Caimi PF, Ardeshna KM, Solh M, Carlo-Stella C, Kahl BS, Hamadani M. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(16):3850-3852.
    doi pubmed
15. Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, et al. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leuk Lymphoma. 2022;63(3):751-754.
    doi pubmed
16. Cencini E, Calomino N, Franceschini M, Dragomir A, Fredducci S, Esposito Vangone B, Lucco Navei G, et al. Survival outcomes of patients with mantle cell lymphoma: a retrospective, 15-year, real-life study. Hematol Rep. 2024;16(1):50-62.
    doi pubmed
17. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
    doi pubmed

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

World Journal of Oncology is published by Elmer Press Inc.